PharmaTher Holdings Ltd. (NCC0)

Overview

PharmaTher Holdings Ltd. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for various diseases and conditions. Founded in 2019 and headquartered in Toronto, Canada, the company has made significant strides in enhancing patient outcomes through novel delivery methods. Its strategic approach involves leveraging partnerships and licensing agreements with leading institutions and companies to advance its product pipeline and harness cutting-edge technologies in drug delivery.

Products and Services

• KETARX (Hydrochloride Injection)

  This product is targeted at treating several conditions, including Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), complex regional pain, and Rett syndrome. It is also developed for use in anesthesia and procedural sedation, as well as treating Ischemia reperfusion injury. The diversity in its applicability showcases PharmaTher's commitment to addressing unmet medical needs across various therapeutic areas.

• KETARX (Microneedle Patch)

  Designed for mental health, neurological, and pain disorders, the KETARX microneedle patch represents a non-invasive delivery system aimed at enhancing patient compliance and experience. The advent of this technology signifies a pivotal shift towards minimizing discomfort associated with traditional injections, potentially revolutionizing the administration of medications for chronic conditions.

• KETARX (On-body Pump)

  PharmaTher is developing this innovative on-body pump for the maintenance of general anesthesia during diagnostic and surgical procedures. The device aims to streamline the delivery of anesthesia, potentially improving the efficiency of medical operations and patient safety by offering a controlled and steady administration of the anesthetic agent.

• PHARMAPATCH (Microneedle Patch Technology)

  This platform encompasses two novel microneedle technologies: hydrogel-forming and gelatin methacryloyl delivery systems. These are principally aimed at the treatment of psychedelics and infectious diseases, offering a transformative approach to delivering treatments with minimal invasiveness and maximized therapeutic efficacy.

Additionally, PharmaTher's strategic collaborations, including license agreements with BioRAE, Inc., the University of Kansas, The Queen's University of Belfast, Gesval SA, and Case Western Reserve University, underscore its commitment to leveraging external expertise and technologies. These partnerships facilitate the development and commercialization of its cutting-edge drug delivery systems and therapeutic solutions, focusing on ketamine's application for various treatments and the development of innovative microneedle patch technologies.